BMS scores first in class with Zeposia

By Megan Brodie 2 years ago | In Companies, Products
  • 2 years ago
Neil MacGregor was among four BMS MDs McAdam has worked with on the campaign.

21 March 2022 BMS’ sphingosine 1-phosphate (S1P) receptor modulator ZEPOSIA (ozanimod), approved in 2020 for…

This is subscriber-only content. Please login to continue reading.